Puretech Health Plc · LSE:PRTC
Puretech Health — H1 2026 Earnings Presentation
23 slides from Puretech Health's earnings presentation, Sep 22, 2026
Slide 1: 2026 Half Year Results
2026 Half Year Results September 22, 2026
Slide 2: Important Information
Important Information The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question-and-answer session and any document or material distributed at or in co
Slide 3: Agenda
Agenda 1. 2026 YTD Highlights 2. PureTech Model & Portfolio Updates 3. Gallop Oncology Updates 4. Our Innovation Framework 5. Financial Highlights & Upcoming Catalysts 3
Slide 4: 2026 YTD Highlights, PureTech Model & Portfolio Updates
2026 YTD Highlights, PureTech Model & Portfolio Updates Robert Lyne Chief Executive Officer 4
Slide 5: 2026 YTD Portfolio & Operational Highlights
2026 YTD Portfolio & Operational Highlights Seaport Therapeutics $260M IPO (Nasdaq: SPTX) Completed GlyphAllo Phase 1 driving simulation trial completed GlyphAgo Phase 1 proof-of-concept trial completed Celea Therapeutics $180M Financing Completed Phase 3 SURPASS-IPF Initiated Gallop Oncol
Slide 6: PureTech Overview
PureTech Overview Deploying our differentiated hub-and-spoke model to give life to science and transform innovation into value Maximize Stakeholder Benefits Strong Fundamentals PATIENT BENEFIT & • Deliver high-impact medicines • Capital-efficient & self-funded model SHAREHOLDER for patients VALUE •
Slide 7: A Diversified Portfolio Well-Positioned for Significant Upside
A Diversified Portfolio Well-Positioned for Significant Upside PureTech Economics Clinical Maturity Equity1 Non-dilutive Celea Therapeutics 1-3% tiered royalties2 on Phase 3 ongoing ~$300M post-money 35.4% deupirfenidone net sales + up to $190M valuation following financing in milestones + 20% subli
Slide 8: Cobenfy Economics to PureTech Based on Analyst Forecasts
Cobenfy Economics to PureTech Based on Analyst Forecasts as of August 11, 2026 Potential ~$50 million in future economic value to PureTech between 2026-20331 based on analyst consensus for Cobenfy sales projections2 ($ in millions) 2026 2027 2028 2029 2030 2031 2032 20331 $250- $359- $431- $474- $49
Slide 9: A Diversified Portfolio Well-Positioned for Significant Upside
A Diversified Portfolio Well-Positioned for Significant Upside PureTech Economics Clinical Maturity Equity1 Non-dilutive Celea Therapeutics 1-3% tiered royalties2 on Phase 3 ongoing ~$300M post-money 35.4% deupirfenidone net sales + up to $190M valuation following financing in milestones + 20% subli
Slide 10: Gallop Oncology Updates
Gallop Oncology Updates Eric Elenko, PhD PureTech Co-founder & Acting Chief Executive Officer of Gallop 10
Slide 11: LYT-200 Targets Galectin-9, a Key Driver in Myeloid Malignancies
LYT-200 Targets Galectin-9, a Key Driver in Myeloid Malignancies Galectin-9: LYT-200: Groundbreaking Target Mutation-Agnostic, Dual MOA • Oncogenic driver and potent Gear 1 immunosuppressor Kills cancer cells • Apoptosis directly • DNA damage • Promotes multiple immunosuppressive pathways Gear 2 • B
Slide 12: Portfolio Progress: Gallop Oncology
Portfolio Progress: Gallop Oncology End-of-Phase 1 meeting with the FDA completed Provided a clear path to advance LYT-200 into Phase 2 STRIDE-MDS trial for the treatment of relapsed/refractory (R/R) high-risk myelodysplastic syndromes (HR-MDS) Fast Track Designation granted by the FDA Facilitat
Slide 13: HR-MDS is a Devastating Bone Marrow Cancer With Poor Survival
High-Risk Myelodysplastic Syndrome (HR-MDS) is a Devastating Bone Marrow Cancer With Poor Survival Poor Survival Outcomes1-5 Significant Unmet Need4 <2 years 1 drug class Frontline Approved for 1st line MDS Median survival following (Hypomethylating Agents or diagnosis with HR-MDS HMAs) 3-6 months 1
Slide 14: Design of Phase 2 STRIDE-MDS Study in R/R HR-MDS
Design of Phase 2 STRIDE-MDS Study in R/R HR-MDS The Study of Two Regimens Investigating Dose and Efficacy of LYT-200 in Relapsed/Refractory High-Risk MDS First Patient In Last Patient In Patient Population (N=125) LYT-200 12 mg/kg + • Post-HMA R/R MDS; high-risk by FDA HMA (N=50) accepted criteria
Slide 15: Our Innovation Framework
Our Innovation Framework Greg Zugates, PhD Vice President, Innovation & Research 15
Slide 16: Launching Innovation From Existing Pharmacology
aunching nnovation rom xisting pharmacology Deploying our L.I.F.E Model to systematically unlock therapeutic potential Goals • At least 3 Concept1-stage programs each year • Additional details around our progress in H1 2027 Approach Target Identify Drugs Pinpoint Design Conduct Significant With Vali
Slide 17: Case Studies of Our Model
Case Studies of Our Model Target Cause of Significant Validated Pharmacology Novel Solutions Limitations Patient Need • PureTech invented & • ~21M people worldwide patented combination of are affected1 • Xanomeline previously xanomeline with demonstrated compelling • Historical antipsychotics • Dose
Slide 18: Financial Highlights & Upcoming Catalysts
Financial Highlights & Upcoming Catalysts Robert Lyne Chief Executive Officer 18
Slide 19: Financial Highlights
Financial Highlights June 30, 2026 December 31, 2025 $ millions $ millions Cash Flow and Liquidity Cash and Cash Equivalents 121.3 252.5 Short-term investments 98.8 24.8 Consolidated Cash, cash equivalents and short-term investments 220.1 277.3 Less: Cash and Cash Equivalents held at non-wholly-owne
Slide 20: Near-term Priorities & Catalysts
Near-term Priorities & Catalysts Equity1 Priority & Catalyst Timing Secure external funding By early Q3 2026 Celea Therapeutics 35.4% Initiate Phase 3 SURPASS-IPF trial in IPF In early Q3 2026 Topline results from Phase 3 SURPASS-IPF trial in IPF H2 2029 Final results from Phase 1b tri
Slide 21: Thank You
GIVING LIFE TO SCIENCE® Thank You PURETECH GIVING LIFE TO SCIENCE’
Slide 22: Appendix
PURETECH © GIVING LIFE TO SCIENCE”
Slide 23: Non-IFRS Measures
Non-IFRS Measures Reported Performance Reported performance considers all factors that have affected the results of our business, as reflected in our condensed consolidated financial statements. Core Performance Core performance measures are alternative performance measures which are adjusted and no